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Abstract
Background: Virus-mediated delivery of therapeutic transgenes to the inflamed colon holds a
great potential to serve as an effective therapeutic strategy for inflammatory bowel disease, since
local, long-term expression of the encoded therapeutic proteins in the colorectal system is
potentially achievable. Viral vectors, derived from adeno-associated virus (AAV), should be very
useful for such therapeutic strategies, particularly because they can establish long-term expression
of transgenes. However, few studies have been carried out to investigate the ability of AAV-based
vectors to transduce the inflamed colon.
Results: AAV, derived from adeno-associated virus serotype 2 (AAV2), showed a limited ability
to transduce colonic cell lines in vitro when used in free form. No appreciable enhancement of the
transduction efficiency was seen when AAV2 particles were attached stably to the surfaces of
microbeads and delivered to target cells in the form of AAV2-microbead conjugates. However, the
transduction efficiency of these colonic cell lines was enhanced substantially when a lectin,
concanavalin A (Con A), was co-attached to the microbead surfaces, to which AAV2 particles had
been conjugated. This considerable infectivity enhancement of AAV2-microbead conjugates by the
co-attachment of Con A may be derived from the fact that Con A binds to α-D-mannosyl moieties
that are commonly and abundantly present in cell-surface carbohydrate chains, allowing the
conjugates to associate stably with target cells. Intracolonical administration of free AAV2 or
AAV2-microbead conjugates without Con A into a mouse colitis model by enema showed very
poor transduction of the colonic tissue. In contrast, the delivery of AAV2 in the form of AAV2-
microbead conjugates bearing Con A resulted in efficient transduction of the inflamed colon.
Conclusion: AAV2-microbead conjugates bearing Con A can serve as efficient gene transfer
agents both for poorly permissive colonic cell lines in vitro and for the inflamed colon in a mouse
colitis model. This efficient transduction system for the inflamed colon should be useful for the
development of gene therapy strategies for inflammatory bowel disease.
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Background
Inflammatory bowel disease (IBD), consisting of two idi-
opathic inflammatory disorders, Crohn's disease and
ulcerative colitis, is characterized by chronic intestinal
inflammation, which causes severe destruction of the
mucosa of the colorectal system [1-4]. An intense, local
immune response is like to be responsible for the initia-
tion and progress of the inflammatory process. A variety
of pro-inflammatory cytokines, such as tumor necrosis
factor-α (TNF-α), interleukin-1β (IL-1β), IL-2, IL-12, and
interferon-γ, are involved in these inflammatory proc-
esses. Thus, one potential therapeutic strategy for IBD is to
repress these inflammatory processes by using anti-
inflammatory cytokines, extracellular domains of the
receptors of pro-inflammatory cytokines, and antagonists
and antibodies against pro-inflammatory cytokines. Gene
therapy approaches are particularly attractive for such
therapeutic strategies, since local, long-term expression of
therapeutic proteins in the colorectal system is potentially
achievable. Previous studies primarily used adenoviral
vectors (Ad5), derived from adenovirus serotype 5, as
gene transfer agents for the inflamed colon. Although the
colorectal system is readily accessible externally, the pres-
ence of the mucous coat on the colonic epithelium and
the dynamic fluidic properties of the colorectal system act
as barriers for the access to the colonic tissue by viral vec-
tors that are administered intracolonically. Thus, adminis-
tration of relatively large amounts of Ad5 was required to
achieve sufficient levels of transgene expression in the
colon [5-7]. We recently showed by using Ad5 with a
mouse chemically induced colitis model that the trans-
duction efficiency of the inflamed colon by Ad5 was very
poor when administered intracolonically in free form, but
that it was enhanced considerably when Ad5 was used in
the form of Ad5-microbead conjugates bearing a lectin,
concanavalin A (Con A), which serves as an effective
anchoring agent for the conjugates [8]. When an Ad5 con-
struct carrying the gene for mouse IL-10, a potent anti-
inflammatory cytokine that is among the most promising
protein therapeutics for IBD [9-19], was administered
intracolonically in the form of Ad5-microbead conjugates
bearing Con A, a considerable increase in the local IL-10
level in the colon was seen. This suggests that intracolon-
ical administration of viral vectors carrying the genes for
IL-10 and other therapeutic proteins may serve as an effec-
tive therapeutic strategy for IBD. However, the use of Ad5
for gene therapy of IBD may be limited to short-term ther-
apeutic strategies, since commonly used Ad5 constructs
are incapable of establishing long-term expression of
transgenes and induce immune responses to transduced
cells due to the expression of viral genes that are also
present in the viral genome. Viral vector species that can
provide sustained expression of therapeutic transgenes
may be more useful for long-term therapy of IBD.
Adeno-associated viral vectors (AAV) are among the most
frequently used viral vector species for in vivo gene therapy
applications [20-25]. AAV, derived from adeno-associated
virus serotype 2 (AAV2), has primarily been used, and
extensive effort is being made to modify or engineer its
properties, such as the infectivity and tropism. Recent
studies are also focused on the development and charac-
terization of AAV constructs that are derived from other
serotypes and variants. AAV possesses several attractive
characteristics as in vivo gene transfer agents: AAV is asso-
ciated with no known pathogenesis, does not stimulate
cell-mediated immune responses, has the ability to trans-
duce a wide range of cell types (i.e., broad tropism), and
has the ability to establish long-term expression of trans-
genes. These multiple attractive properties, particularly its
ability to provide sustained expression of transgenes, sug-
gest that AAV may serve as a useful viral vector species for
the development of gene therapy strategies for IBD. How-
ever, to our knowledge, AAV-based vectors were not previ-
ously tested for the transduction of the inflamed colon.
In the present work, we investigated if AAV2 could be used
for efficient transduction of the inflamed colon in mice
toward its application to gene therapy of IBD. AAV2,
when used in free form, showed a limited ability to trans-
duce colonic cell lines in vitro. In addition, the transduc-
tion efficiency of the inflamed colon in a mouse colitis
model was very poor when free AAV2 was administered
intracolonically by enema. Thus, we examined if the trans-
duction efficiencies of colonic cell lines and the inflamed
colon in mice could be enhanced by the delivery of AAV2
in the form of virus-microbead conjugates bearing lectin
as an anchoring agent.
Results
We initially investigated, by using in vitro systems, the
infectivity of AAV2 for two colonic cell lines, COLO 205
(human colorectal adenocarcinoma) and MIP-101
(human colorectal carcinoma), along with the human cer-
vical adenocarcinoma cell line HeLa, which is known to
be highly permissive to infection by AAV2. We used an
AAV2 construct, AAV2.CMV-LacZ, which carries the bacte-
rial lacZ (β-galactosidase) gene under the control of the
human cytomegalovirus immediate/early promoter. The
infectivity of AAV2.CMV-LacZ in free form for these two
colonic cell lines was lower by one to two orders of mag-
nitude than that for HeLa cells (data not shown), suggest-
ing that colonic cells may be poorly permissive to
infection by AAV2. This result prompted us to investigate
if the delivery of AAV2 to target cells in the form of virus-
microbead conjugates could enhance the transduction
efficiency of colonic cells.
Preparation of virus-microbead conjugates with AAV2
(AAV2-microbead conjugates) essentially followed theBMC Biotechnology 2007, 7:83 http://www.biomedcentral.com/1472-6750/7/83
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method established for Ad5 [8,26,27] with the optimiza-
tion of each step. In this method, biotin groups are
attached covalently to the surfaces of viral particles by
biotinylation using a water-soluble, amino-reactive bioti-
nylation reagent (sulfo-NHS-LC-biotin; Pierce), followed
by the removal of non-virion-associated biotinylation rea-
gent. The resulting surface-biotinylated viral particles are
attached to microbeads, on which the biotin-binding pro-
tein, avidin or streptavidin [28-31], is immobilized cova-
lently in high density (avidin- or streptavidin-coated
microbeads, respectively). Optimal conditions for the sur-
face biotinylation of AAV2 particles, where the viral sur-
faces are biotinylated without disturbing the viral
infectivity, were initially determined. AAV2.CMV-LacZ
was treated with varying concentrations of sulfo-NHS-LC-
biotin at room temperature (~22°C) for 45 min in the
dark, followed by the termination of biotinylation reac-
tion. The resulting AAV2 particles were analyzed for their
infectivity on HeLa cells that are highly permissive to
infection by AAV2 (Fig. 1). The viral infectivity decreased
sharply with increasing the concentration of sulfo-NHS-
LC-biotin during biotinylation reaction, as seen previ-
ously with the biotinylation of Ad5 [26,27,32]. When the
concentration of sulfo-NHS-LC-biotin was 0.5 mg/ml or
higher, considerable reduction of the viral infectivity was
seen (p < 0.01). However, treatment with sulfo-NHS-LC-
biotin at concentrations up to 0.25 mg/ml showed a lim-
ited effect on the viral infectivity. This suggests that the
surfaces of AAV2 particles may be biotinylated by using
sulfo-NHS-LC-biotin in this concentration range with
minimal effect on the viral infectivity. To test if the viral
surfaces were indeed biotinylated, particularly when the
concentration of sulfo-NHS-LC-biotin was relatively low,
excess avidin was added to AAV2 after biotinylation reac-
tion, and the viral infectivity was then analyzed on HeLa
cells. This method allows the assessment of the presence
of biotin groups on the viral surfaces, since the viral infec-
tivity is significantly reduced by the binding of avidin to
viral-surface biotin groups, as shown previously for bioti-
nylated Ad5 particles [26]. The addition of excess avidin
severely reduced the infectivity of AAV2 particles that had
been treated with sulfo-NHS-LC-biotin, while it showed
little effect on the infectivity of unmodified AAV2.CMV-
LacZ (Fig. 1). When AAV2.CMV-LacZ was treated with
sulfo-NHS-LC-biotin at concentrations of 0.25 mg/ml
and higher, the addition of excess avidin ablated the viral
infectivity completely (p < 0.01). When AAV2.CMV-LacZ
was treated with 50 μg/ml sulfo-NHS-LC-biotin, the viral
infectivity became slightly higher than that of unmodified
AAV2.CMV-LacZ (p < 0.01), but the addition of excess avi-
din reduced the viral infectivity considerably (p < 0.01).
This suggests that the treatment of AAV2 with sulfo-NHS-
LC-biotin at this concentration can maximally maintain
the viral infectivity, while the viral surfaces can indeed be
biotinylated. Repeated experiments reveal that the opti-
mal conditions for surface biotinylation of AAV2 particles
involve the treatment with sulfo-NHS-LC-biotin at 30 –
70 μg/ml, where the viral infectivity is hardly affected and
the majority, if not all, of the viral particles are indeed
biotinylated.
Preparation of AAV2-microbead conjugates was carried
out by using AAV2.CMV-LacZ that had been treated with
50 μg/ml sulfo-NHS-LC-biotin as above. After the termi-
nation of biotinylation reaction, biotinylated AAV2 parti-
cles were dialyzed to remove non-virion-associated
biotinylation reagent and mixed with avidin-coated fluo-
rescent microbeads, in which a rhodamine derivative is
encapsulated (diameter, 480 nm; specific gravity, 1.06 g/
cm3) (Spherotech). Infectivity analysis of the supernatant
after the centrifugation of the mixtures revealed that
greater than 95% of the AAV2 particles used were bound
to avidin-coated microbeads, indicating that the binding
of biotinylated AAV2 particles to avidin-coated
microbeads was highly efficient. The resulting AAV2-
Infectivity analysis of AAV2 treated with sulfo-NHS-LC-biotin Figure 1
Infectivity analysis of AAV2 treated with sulfo-NHS-LC-
biotin. AAV2.CMV-LacZ was treated with varying concentrations 
of sulfo-NHS-LC-biotin at room temperature for 45 min in the 
dark, followed by the addition of excess glycine to terminate the 
biotinylation reaction. The resulting biotinylated AAV2 prepara-
tions were applied to HeLa cells (5 × 106 AAV2 particles per well), 
which had been grown in 24-well plates at 37°C for 24 hr (initial 
cell number, 5 × 104 cells per well), and incubated at 37°C for 48 
hr. Cells were fixed with glutaraldehyde, stained for β-galactosi-
dase (LacZ) activity using X-gal as the substrate. Then, the number 
of infected cells, which were stained blue, in each well was 
counted under a light microscope (- -). The same analysis was also 
performed on biotinylated AAV2 preparations, to which excess 
Neutralite avidin (100 μg per 5 × 106 AAV2 particles) had been 
added (- -). Each datum shown is the average number of infected 
cells per well with a standard deviation (n = 26).
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microbead conjugates (9.2 AAV2 particles per microbead)
were analyzed for their infectivity on HeLa, COLO 205,
and MIP-101 cells. The infectivity of these AAV2-
microbead conjugates was lower than or equivalent to
free, unmodified AAV2.CMV-LacZ (HeLa, p < 0.01; COLO
205 and MIP-101, p > 0.05) (Fig. 2). This suggests that the
ability of these conjugates to associate with target cells
may be similar to that of free AAV2 particles, since the
microbeads, used as carriers of AAV2 particles, have phys-
iological specific gravity. This notion was supported by
fluorescence microscopic analysis of target cells, in which
only limited amounts of cell-associated fluorescence,
derived from the avidin-coated microbeads used, were
seen after AAV2-microbead conjugates were applied and
incubated for 24 hr (data not shown).
We previously showed with Ad5-microbead conjugates
[8,27] that the co-attachment of a lectin, Con A, to the
microbead surface allowed the conjugates to associate sta-
bly with target cells due to the ability of Con A to bind to
commonly occurring α-D-mannosyl moieties in cell-sur-
face carbohydrate chains, resulting in efficient transduc-
tion of the target cells. We assessed if the ability of AAV2-
microbead conjugates to associate with target cells and
subsequently transduce them could also be enhanced by
the co-attachment of lectins on the microbead surfaces.
AAV2-microbead conjugates were prepared as above (9.2
AAV2 particles per microbead), and then biotinylated
forms of several lectins with different carbohydrate specif-
icities (see the Methods section) were co-attached to the
microbead surfaces. These conjugates were analyzed for
their infectivity on HeLa, COLO 205, and MIP-101 cells
(Fig. 2). For HeLa cells, which are highly permissive to
infection by free AAV2, the co-attachment of lectins to the
microbead surface showed little effect on the infectivity of
AAV2-microbead conjugates (p > 0.05 for all of the lectins
used). In contrast, the infectivity of AAV2-microbead con-
jugates on COLO 205 and MIP-101 cells was enhanced
considerably when certain lectins were co-attached to the
microbead surfaces. In particular, the co-attachment of
Con A showed dramatic enhancement of the infectivity of
AAV2-microbead conjugates for these colonic cell lines (p
< 0.01 for both COLO 205 and MIP-101). When COLO
205 cells were used as targets, the infectivity of AAV2-
microbead conjugates bearing Con A became approxi-
mately 30-fold higher than those of free, unmodified
AAV2 or AAV2-microbead conjugates without lectin (p <
0.01). Similarly, the co-attachment of Con A enhanced
the infectivity of AAV2-microbead conjugates for MIP-101
cells by approximately 4-fold, as compared to free,
unmodified AAV2 or AAV2-microbead conjugates with-
out lectin (p < 0.01). No appreciable effect on the mor-
phology and viability of target cells was seen for any of
these cell lines when Con A was co-attached to the
microbead surfaces. Other lectins tested showed little
Effect of the co-attachment of lectins to the microbead sur- faces on the infectivity of AAV2-microbead conjugates Figure 2
Effect of the co-attachment of lectins to the microbead 
surfaces on the infectivity of AAV2-microbead conju-
gates. AAV2.CMV-LacZ was biotinylated with sulfo-NHS-LC-
biotin at 50 μg/ml, followed by the removal of non-virion-associ-
ated biotinylation reagent by dialysis. AAV2-microbead conjugates 
were prepared by the attachment of biotinylated AAV2 particles 
to the surfaces of avidin-coated fluorescent microbeads (480 nm 
in diameter) (9.2 AAV2 particles per microbead). To these AAV2-
microbead conjugates, a biotinylated form of each lectin was 
added in excess (0.2 μg biotinylated lectin per 107 avidin-coated 
microbeads), followed by the removal of unbound lectin mole-
cules by centrifugation. The infectivity of these AAV2-microbead 
conjugates with and without lectin was analyzed on HeLa, COLO 
205, and MIP-101 cell lines. Cells were cultured in 24-well plates 
at 37°C for 24 hr (initial cell number per well: HeLa, 5 × 104; 
COLO 205, 1 × 105; MIP-101, 7.5 × 104). AAV2-microbead conju-
gates bearing each lectin, along with free unmodified AAV2.CMV-
LacZ, free biotinylated AAV2.CMV-LacZ, and AAV2-microbead 
conjugates without lectin, were applied to target cells (a total of 1 
× 107 AAV2 particles per well) and incubated at 37°C for 48 hr. 
Cells were fixed with glutaraldehyde and stained for β-galactosi-
dase activity using X-gal as the substrate. Then, the number of 
infected cells in each well was counted under a light microscope. 
Each datum shown is the average number of infected cells per well 
with a standard deviation (n = 16). A, free, unmodified 
AAV2.CMV-LacZ; B, free, biotinylated AAV2.CMV-LacZ; C, 
AAV2-microbead conjugates without lectin; D – J, AAV2-
microbead conjugates bearing lectin (D, Con A; E, horse gram 
agglutinin; F, peanut agglutinin; G, castor bean agglutinin I; H, soy-
bean agglutinin; I, furze gorse agglutinin I; and J, wheat germ agglu-
tinin).
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effect on the infectivity of AAV2-microbead conjugates on
COLO 205 and MIP-101 cells, except for castor bean
agglutinin I that enhanced the infectivity of the conjugates
for COLO 205 cells by approximately 8-fold (p < 0.01).
The considerable infectivity enhancement of AAV2-
microbead conjugates by the co-attachment of Con A for
these poorly permissive colonic cell lines may be derived
from the fact that Con A binds to α-D-mannosyl moieties
that are commonly and abundantly present in cell-surface
carbohydrate chains, allowing the conjugates to associate
with target cells with much higher efficiencies.
The effect of the number of AAV2 particles per microbead
on the infectivity of AAV2-microbead conjugates bearing
Con A was analyzed for the three cell lines used above,
along with a human colorectal adenocarcinoma cell line,
SW620, which was previously found to have an even
lower permissivity to infection by free AAV2 than COLO
205 and MIP-101 cells. AAV2-microbead conjugates were
prepared with varying numbers of AAV2 particles per
microbead (0 – 676 AAV2 particles per microbead). The
infectivity of these conjugates with and without the co-
attachment of Con A, along with free, unmodified
AAV2.CMV-LacZ as a control, was analyzed (Fig. 3). In
this analysis, the amount of total AAV2 particles per well
Effect of the number of AAV2 particles per microbead on the infectivity of AAV2-microbead conjugates with and without Con  A Figure 3
Effect of the number of AAV2 particles per microbead on the infectivity of AAV2-microbead conjugates with and with-
out Con A. AAV2-microbead conjugates were prepared as in Fig. 2 at varying numbers of AAV2 particles per microbead (0 – 676 AAV2 
particles per microbead). These conjugates with and without the co-attachment of Con A were analyzed for their infectivity on HeLa, 
COLO 205, MIP-101, and SW620 cell lines. Cells were cultured in 24-well plates at 37°C for 24 hr (initial cell number per well: HeLa, 5 
× 104; COLO 205, 1 × 105; MIP-101, 7.5 × 104; SW620, 1 × 105). AAV2-microbead conjugates with and without Con A, along with free, 
unmodified AAV2.CMV-LacZ, were applied to target cells (1 × 107 AAV2 particles per well for HeLa, and 1 × 108 AAV2 particles per well 
for COLO 205, MIP-101, and SW620) and incubated at 37°C for 48 hr. Cells were fixed with glutaraldehyde and stained for β-galactosi-
dase activity using X-gal as the substrate. Then, the number of infected cells in each well was counted under a light microscope. Open 
bars, without Con A; solid bars, with Con A. Each datum shown is the average number of infected cells per well with a standard deviation 
(n = 16).
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was kept constant for each cell line. This means that the
total number of AAV2-microbead conjugates per well
decreased with increasing the number of AAV2 particles
per microbead. For HeLa cells that are highly permissive
to infection by free AAV2, the number of AAV2 particles
per microbead had little effect on the infectivity of AAV2-
microbead conjugates, which was similar to that of free
AAV2. The co-attachment of Con A to the microbead sur-
faces also showed little effect on the infectivity of the con-
jugates (p > 0.05 for all of the numbers of AAV2 particles
per microbead tested), suggesting that the infection proc-
ess was initiated primarily by direct binding of AAV2 par-
ticles on the microbead surfaces to cell-surface heparan
sulfate, not by the binding of Con A on the microbead sur-
faces to cell-surface carbohydrate chains. In contrast, the
number of AAV2 particles per microbead showed a dra-
matic effect on the infectivity of the conjugates for the
three colonic cell lines, particularly when Con A was co-
attached to the microbead surfaces. For COLO 205 and
MIP-101 cells, the number of AAV2 particles per
microbead had a limited effect on the infectivity when
AAV2-microbead conjugates were used without the co-
attachment of Con A. However, when Con A was co-
attached to the microbead surfaces, the infectivity of the
conjugates became higher than those without Con A, and
the highest infectivity was seen when the number of AAV2
particles per microbead was 19.8 for both COLO 205 and
MIP-101 cell lines. Similarly, both free AAV2 and AAV2-
microbead conjugates without Con A had extremely low
infectivity for SW620 cells, but the co-attachment of Con
A to the microbead surfaces substantially enhanced the
infectivity of AAV2-microbead conjugates (p < 0.01 for all
of the numbers of AAV2 particles per microbead tested,
except at 676 AAV2 particles per microbead), particularly
when the number of AAV2 particles per microbead was
19.8. Repeated experiments reveal that the infectivity of
AAV2-microbead conjugates bearing Con A for these
poorly permissive colonic cell lines became maximal
when the number of AAV2 particles per microbead was in
a range between 10 and 60.
The results of in vitro experiments described above suggest
that AAV2-microbead conjugates bearing Con A may offer
enhanced transduction of the colon over free AAV2 and
AAV2-microbead conjugates without lectin when admin-
istrated intracolonically by enema. To test this, we used a
mouse acute colitis model, in which colonic inflamma-
tion was induced chemically by intracolonical administra-
tion of 2,4,6-trinitrobenzenesulfonic acid (TNBS) [8,33].
AAV2-microbead conjugates were prepared using
AAV2.CMV-LacZ at 32 AAV2 particles per microbead.
These conjugates with the co-attachment of Con A were
administered intracolonically into mice with TNBS-
induced colitis by enema [a total of 1 × 1010 AAV2 parti-
cles per mouse]. As controls, free, unmodified
AAV2.CMV-LacZ and AAV2-microbead conjugates with-
out Con A were administered in the same manner. At 48-
hr post-administration, mice were euthanized, and their
colons were collected, fixed, and sectioned. These colon
sections were stained for lacZ expression using 5-bromo-
4-chloro-3-indoyl-β-D-galactopyranoside (X-gal) as the
substrate (Fig. 4). When free AAV2.CMV-LacZ was admin-
istered intracolonically, no appreciable expression of the
lacZ gene was seen (Fig. 4A), indicating the low permissiv-
ity of colonic tissue to infection by free AAV2. The trans-
duction efficiency of the inflamed colon remained very
low when AAV2.CMV-LacZ was used in the form of AAV2-
microbead conjugates without Con A (Fig. 4B). In con-
trast, intracolonical administration of AAV2.CMV-LacZ in
the form of AAV2-microbead conjugates bearing Con A
resulted in very efficient transduction of the colonic tissue
(Figs. 4C and 4D). Transduction was seen primarily in the
mucosal layer, to which administered AAV2-microbead
conjugates should have easy access due to its destruction
caused by colonic inflammation. Absorptive and goblet
cells in the colon epithelium, along with lamina propria
in crypts, were primarily transduced. In addition, the mus-
cularis mucosa and the sub-mucosal layer may also be
transduced, suggesting that AAV2-microbead conjugates
not only infected the surfaces of colonic epithelia but also
migrated into and subsequently transduced colonic tissue.
Since colonic epithelial cells actively turn over and are
rapidly shed, the transduction of these cells alone should
provide only short-term production of therapeutic pro-
teins in the inflamed colon, offering limited effectiveness
for the therapy of IBD. In contrast, the transduction of
other cell types in the muscularis mucosa and the sub-
mucosal layer should offer sustained expression of trans-
genes, which should be useful for the development of
long-term therapeutic strategies for IBD.
We also investigated the spatial relationship between
transduction sites and the location of tissue-associated
microbeads in colon sections from mice, which received
AAV2-microbead conjugates with and without the co-
attachment of Con A (Fig. 5). Colon sections were initially
stained for lacZ expression using X-gal as the substrate,
and stained sections were examined under a fluorescence
microscope to detect microbead-derived red fluorescence.
Few microbeads were detected in colonic tissue, which
received AAV2-microbead conjugates without Con A
(data not shown). This suggests that these conjugates have
a limited ability to associate with colonic tissue upon
intracolonical administration. In contrast, many tissue-
associated microbeads were seen in colon sections when
AAV2 was used in the form of AAV2-microbead conju-
gates bearing Con A (Fig. 5), suggesting that the co-attach-
ment of Con A allowed the conjugates to associate stably
with colonic tissue upon intracolonical administration.
The same colon sections were then counter-stained withBMC Biotechnology 2007, 7:83 http://www.biomedcentral.com/1472-6750/7/83
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eosin/phloxine B and examined under a light microscope
to detect the transduction by AAV2. Efficient transduction
was seen at locations where many tissue-associated
microbeads were present. This reveals that the co-attach-
ment of Con A makes AAV2-microbead conjugates capa-
ble of associating stably with colonic tissue, allowing the
attached AAV2 particles to mediate efficient transduction
of colonic cells.
Discussion
In the present study, we have demonstrated that AAV2-
microbead conjugates bearing Con A can serve as efficient
gene transfer agents both for colonic cell lines in vitro and
for the inflamed colon in a mouse colitis model. Con A
was found to be an effective anchoring agent for AAV2-
microbead conjugates, providing efficient transduction of
target cells and tissues both in vitro and in vivo. The infec-
tivity enhancement by the co-attachment of Con A is
likely derived from the ability of Con A on the microbead
surfaces to allow the conjugates to associate stably with
target cells or tissues due to its ability to bind to com-
monly occurring α-D-mannosyl moieties in cell-surface
carbohydrate chains. The ability to associate stably with
target tissue may be particularly important for the trans-
duction of the colorectal system, where the dynamic flu-
idic properties inhibit stable association of viral particles
with colonic tissues. We also analyzed the transduction of
the normal colons (i.e., without colonic inflammation) in
Transduction of the inflamed colon in mice by AAV2-microbead conjugates bearing Con A upon intracolonical administration Figure 4
Transduction of the inflamed colon in mice by AAV2-microbead conjugates bearing Con A upon intracolonical adminis-
tration. AAV2-microbead conjugates with and without Con A were prepared at 32 AAV2 particles per microbead, as described in Figs. 
3 and 4. These conjugates, along with free, unmodified AAV2.CMV-LacZ, were administered intracolonically into mice with TNBS-
induced colitis by enema (a total of 1 × 1010 AAV2 particles in 100 μl PBST per mouse). At 48-hr post-administration, mice were eutha-
nized, and cryosections of their colons were prepared. These colon sections were stained for β-galactosidase activity using X-gal as the 
substrate, followed by counter-staining with eosin/phloxine B. Stained colon sections were examined under a light microscope. A, free, 
unmodified AAV2.CMV-LacZ; B, AAV2-microbead conjugates without Con A; C and D, AAV2-microbead conjugates bearing Con A. AC, 
absorptive cell; GC, goblet cell; LP, lamina propria; ME, muscularis externa; MM, muscularis mucosa; Muc, mucosal layer; SubM, sub-
mucosal layer. Representative images are shown.BMC Biotechnology 2007, 7:83 http://www.biomedcentral.com/1472-6750/7/83
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mice by AAV2 upon intracolonical administration. Under
the conditions used for the transduction of the colons
with TNBS-induced colitis (Fig. 4), no appreciable trans-
duction of the normal colons was seen when AAV2 was
used either in free form or in the form of AAV2-microbead
conjugates with or without the co-attachment of Con A
(data not shown). These results suggest that the exposure
of colonic tissue by the destruction of the mucous coat on
the colonic epithelium upon the development of TNBS-
induced colitis is critical for AAV-microbead conjugates
bearing Con A to associate stably to the colonic tissue and
subsequently transduce colonic cells.
A different strategy for the construction of AAV2-
microbead conjugates was previously reported [34]. In
this strategy, microbeads are coated with the primary
receptor of AAV2, heparan sulfate, to which unmodified
AAV2 particles are attached. We tested this strategy in vitro
by using avidin-coated microbeads with physiological
specific gravity, used in this study, with unmodified
Spatial relationship between transduction sites and the location of tissue-associated microbeads in the inflamed colon upon  intracolonical administration of AAV2-microbead conjugates bearing Con A Figure 5
Spatial relationship between transduction sites and the location of tissue-associated microbeads in the inflamed colon 
upon intracolonical administration of AAV2-microbead conjugates bearing Con A. Colon sections, prepared from mice that 
received AAV2-microbead conjugates with and without the co-attachment of Con A, were stained for β-galactosidase activity using X-gal 
as the substrate. Stained sections (without counter-staining) were examined under a fluorescence microscope to detect microbead-
derived red fluorescence (right images). Then, colon sections were counter-stained with eosin/phloxine B and subjected to light micro-
scopic analysis for transduction sites (left images), in which images at the same location as fluorescence detection of tissue-associated 
microbeads above were captured. Colon sections, derived from mice that received AAV2-microbead conjugates without Con A, showed 
no appreciable transduction or tissue-associated microbeads (data not shown). The two pairs of images shown are derived from colon 
sections of mice that received AAV2-microbead conjugates bearing Con A. MM, muscularis mucosa; Muc, mucosal layer; SubM, sub-
mucosal layer. Representative images are shown.BMC Biotechnology 2007, 7:83 http://www.biomedcentral.com/1472-6750/7/83
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AAV2.CMV-LacZ. No appreciable enhancement of the
infectivity was seen with these AAV2-microbead conju-
gates, as compared to free AAV2.CMV-LacZ, when ana-
lyzed using cultured colonic cell lines (data not shown).
This may be derived from the physiological specific grav-
ity of such conjugates, with which their ability to associate
with target cells may be similar to that of free AAV2, as
seen with AAV2-microbead conjugates without lectin in
this study. The presence of large amounts of heparan sul-
fate on the microbead surfaces may also inhibit efficient
binding of attached AAV2 particles to cell-surface heparan
sulfate. In addition, this strategy does not allow the co-
attachment of other materials on the microbead surfaces,
to which AAV2 particles have been conjugated. Thus, the
use of such conjugates for the transduction of the
inflamed colon may be limited, since their association
with colonic tissue upon intracolonical administration
should be inefficient without the co-attachment of an
appropriate anchoring agent, such as Con A. In contrast, a
key strength of our strategy is that almost any materials
can readily be co-attached to the microbead surfaces, to
which AAV2 particles (or other viral particles used) have
been conjugated. This should allow the properties and
functionality of AAV2-microbead conjugates to be con-
trolled or engineered in a systematic manner. In addition,
our strategy should be applicable to AAV-based vectors
that are derived from not only AAV2 but also other sero-
types and variants. This should make our strategy applica-
ble to the transduction of a wide range of cell types and
tissue targets.
Conclusion
This study has demonstrated that the delivery of AAV2 in
the form of AAV2-microbead conjugates bearing the lectin
Con A provides considerable enhancements of the trans-
duction efficiency both for poorly permissive colonic cell
lines in vitro and for the inflamed colon in mice upon
intracolonical administration by enema. In particular, the
co-attachment of Con A to the microbead surfaces as an
anchoring agent was found essential for efficient transduc-
tion of colonic cells by AAV2-microbead conjugates both
in vitro and  in vivo. With this efficient AAV2-mediated
transduction system for the inflamed colon, it should now
be possible to investigate, systematically, the efficacy of
potential gene therapy strategies for IBD by using the
genes for a variety of different protein therapeutics. Such
protein therapeutics should include the anti-inflamma-
tory cytokine IL-10, antibodies against the pro-inflamma-
tory cytokine TNF-α, and the extracellular domain of the
TNF-α receptor, each of which has shown potential effec-
tiveness for the therapy of IBD.
Methods
AAV2 construct
An AAV2 construct, AAV2.CMV-LacZ, was obtained from
the Vector Core, Harvard Gene Therapy Initiative, Dana-
Farber/Harvard Cancer Center, Boston, MA. AAV2.CMV-
LacZ, derived from adeno-associated virus serotype 2, car-
ries the bacterial lacZ (β-galactosidase) gene with a
nuclear localization signal under the control of the
human cytomegalovirus immediate/early promoter with
the polyadenylation signal of the bovine growth hormone
gene. Prior to use, AAV2.CMV-LacZ was purified twice by
affinity chromatography using heparin as the ligand [35]
(heparin-agarose type I; Sigma).
Cell lines
The following four human cell lines were used as targets
for in vitro experiments: HeLa (cervical adenocarcinoma),
COLO 205 (colorectal adenocarcinoma), MIP-101 (color-
ectal carcinoma), and SW620 (colorectal adenocarci-
noma). HeLa, COLO 205, and SW620 were obtained
from the American Type Culture Collection (Manassas,
VA), and MIP-101 was a generous gift from Peter Thomas,
Boston University School of Medicine, Boston, MA. HeLa
and SW620 cells were maintained in Dulbecco's modified
Eagle's medium (BioWhittaker), supplemented with 10%
fetal bovine serum (BioWhittaker). COLO 205 and MIP-
101 cells were maintained in RPMI 1640 medium (BioW-
hittaker), supplemented with 10% fetal bovine serum, 4.5
mg/ml glucose, 1.5 mg/ml sodium bicarbonate, and 10
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.
Biotinylation of AAV2 particles
A water-soluble, amino-reactive biotinylation reagent,
sulfo-NHS-LC-biotin (Pierce) [8,26,27,32], was used to
biotinylate AAV2 particles. Sulfo-NHS-LC-biotin was
freshly dissolved in Dulbecco's phosphate-buffered saline
(PBS) containing 0.05% Tween 20 (PBST) and added to
AAV2.CMV-LacZ in PBST (1 × 1010 AAV2 particles/ml) at
varying final concentrations (0 – 2 mg/ml). The mixtures
were incubated at room temperature (~22°C) for 45 min
in the dark, and the biotinylation reaction was terminated
by the addition of glycine in PBS to a final concentration
of 10 mM. The resulting biotinylated AAV2 particles were
analyzed for their infectivity by using HeLa cells as the tar-
gets. HeLa cells were grown in 24-well plates (5 × 104 cells
per well) at 37°C for 24 hr. Then, each biotinylated
AAV2.CMV-LacZ preparation was applied to target cells (5
× 106 AAV2 particles per well containing 500 μl of culture
media) and incubated at 37°C for 48 hr. Cells were fixed
with 0.5% glutaraldehyde and stained for β-galactosidase
(LacZ) activity using X-gal as the substrate. The numbers
of infected, lacZ-expressing cells were counted under a
light microscope. The same analysis was also performed
by using biotinylated AAV2.CMV-LacZ preparations, to
which excess amounts of Neutralite avidin (Southern Bio-BMC Biotechnology 2007, 7:83 http://www.biomedcentral.com/1472-6750/7/83
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technology Associates) (100 μg per 5 × 106 AAV2 parti-
cles) had been added, to assess the biotinylation of the
viral surfaces.
Preparation of AAV2-microbead conjugates with and 
without the co-attachment of lectin
Preparation of AAV2-microbead conjugates was carried
out by using AAV2.CMV-LacZ and avidin-coated fluores-
cent polystyrene microbeads (diameter, 480 nm; specific
gravity, 1.06 g/cm3) (Spherotech), in which a rhodamine
derivative (red fluorescence) is encapsulated. AAV2.CMV-
LacZ was biotinylated with sulfo-NHS-LC-biotin at 50 μg/
ml as above. After the termination of biotinylation reac-
tion by the addition of glycine, biotinylated AAV2 parti-
cles were dialyzed against PBST to remove non-virion-
associated biotinylation reagent. Dialyzed AAV2 particles
were mixed with avidin-coated microbeads at appropriate
ratios. The mixtures were incubated at room temperature
for 30 min with occasional mixing, followed by the
removal of unbound AAV2 particles by centrifugation.
The supernatant fraction, which contained unbound
AAV2 particles, was analyzed for its infectivity on HeLa
cells to determine the number of bound AAV2 particles
per microbead.
The following lectins in biotinylated form were obtained
from Vector Laboratories [the carbohydrate structure(s),
to which each lectin binds, is indicated in bracket]: Con A
from Jack bean (Canavalia ensiformis) seeds [mannose];
agglutinin from horse gram (Dolichos biflorus) seeds [N-
acetylgalactosamine]; agglutinin from peanuts (Arachis
hypogaea) [galactosyl (β-1,3)N-acetylgalactosamine];
agglutinin I from castor bean (Ricinus communis) seeds
[galactose and N-acetylglucosamine]; agglutinin from
soybean (Glycine max) seeds [N-acetylgalactosamine and
galactose]; agglutinin I from furze gorse (Ulex europaeus)
seeds [fucose]; and agglutinin from wheat germ (Triticum
vulgaris) [N-acetylglucosamine]. The co-attachment of a
lectin to the microbead surface was carried out by the
addition of an excess amount of a biotinylated form of the
lectin to AAV2-microbead conjugates (0.2 μg biotinylated
lectin per 107 avidin-coated microbeads), followed by the
removal of unbound lectin molecules by centrifugation.
Infectivity analysis of AAV2-microbead conjugates with 
and without lectin
The infectivity of AAV2-microbead conjugates with and
without the co-attachment of lectin, prepared above, was
analyzed by using HeLa, COLO 205, MIP-101, and
SW620 cell lines as targets. Cells were cultured in 24-well
plates at 37°C for 24 hr. AAV2-microbead conjugates with
and without lectins, along with free, unmodified
AAV2.CMV-LacZ and free, biotinylated AAV2.CMV-LacZ
as controls, were applied to each well. The actual numbers
of target cells and AAV2 particles per well for each cell line
are given in the legends to Figs. 2 and 3. Cells were incu-
bated at 37°C for 48 hr, fixed with glutaraldehyde, and
stained for β-galactosidase activity using X-gal as the sub-
strate. Then, the numbers of infected cells were counted
under a light microscope.
In vivo transduction of the inflamed colon in mice by 
AAV2-microbead conjugates
All animal procedures were carried out in accordance with
NIH guidelines following approval by the Harvard Medi-
cal Area Standing Committee on Animals. A mouse acute
colitis model was prepared by intracolonical administra-
tion of TNBS (Sigma) (0.75 mg in 100 μl of 50% ethanol
per mouse) into Balb/c mice (6 – 8 weeks old; Taconic) by
enema, as described previously [8]. These mice with
TNBS-induced colitis were subjected to experimentation
at 48-hr post-administration of TNBS, at which time
severe destruction of the mucosal layer was seen in the
colon and the mice lost their weight by 10 – 15% during
the 48-hr period. AAV2-microbead conjugates bearing
Con A were prepared by using AAV2.CMV-LacZ at 32
AAV2 particles per microbead, as described above. These
conjugates were administered intracolonically into mice
with TNBS-induced colitis by enema (a total of 1 × 1010
AAV2 particles in 100 μl PBST per mouse). As controls,
free, unmodified AAV2.CMV-LacZ and AAV2-microbead
conjugates without Con A were administered into mice
with TNBS-induced colitis in the same manner. At 48-hr
post-administration, mice were euthanized, and their
colons were collected. These colons samples were frozen
in tissue freezing media (Tissue-Tek O.C.T. compound,
Miles), followed by the preparation of cryosections (thick-
ness, 5 – 7 μm). Colon sections were stained for β-galac-
tosidase activity using X-gal as the substrate, with counter-
staining with eosin/phloxine B. Stained colon sections
were examined under a light microscope (Axioscop 2, Carl
Zeiss).
When the spatial relationship between transductions sites
and the location of tissue-associated microbeads was ana-
lyzed, colon sections were stained for β-galactosidase
activity using X-gal as the substrate. Stained colon sections
(without counter-staining) were initially examined under
a fluorescence microscope (Axioscop 2) to detect tissue-
associated microbeads (red fluorescence). Then, the colon
sections were counter-stained with eosin/phloxine B and
examined under a light microscope (Axioscop 2) for the
detection of transduction sites, where images at the same
location as fluorescence detection of tissue-associated
microbeads above were captured.
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